Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases

##plugins.themes.academic_pro.article.sidebar##

Published Jan 21, 2010
Download
pdf
Vol. 88 No. 1 (2010): Issue Jan 2010

##plugins.themes.academic_pro.article.main##

N.Ezzine Sebai
N Mrabet
A Khaled
F Zeglaoui
M Kharfi
B Fazaa
M.R Kamoun

Abstract

Background : Leishmaniasis is wide spread parasitic disease considered to be endemic in 88 countries in both old and new world. The standard treatment remains Meglumine antimoniate.
Aim : We study the side effects of systemic meglumine antimoniate in cutaneous leishmaniasis.
Methods :We conduct a retrospective study covering 3-year period (2002- 2005). All medical reports of cutaneous leishmaniasis treated by systemic Meglumine antimoniate are reviewed.
Results : The study comprise 63 patients all treated by systemic meglumine antimoniate at the dose of 60mg/kg/day for 10-15 days. Side effects were noted in 15 cases (12 females and 3 males).The subject’s age range from 11 to 78 years. Stibio-intolerance (fever, rash, arthralgia, abdominal pain) was observed in 12 cases and stibiotoxicity in 3 cases: precordialgies 1 case, hyperamylasemia and increase liver enzyme: 1 case, pancytopenia, renal and hepatic failure leading to death: 1 case, skin eruption: 7 cases, pruritis and erythema in the site of injection: 5 cases, urticaria: 1 case. Meglumine  antimoniate was stopped in 13 cases
Conclusion : Meglumine antimoniate is the generally recommended treatment of cutaneous leishmaniasis. In spite of the rarity of Glucantime’s side effects, we recommend a careful survey especially in older patients.

Keywords:

Cutaneous Leishmaniasis, Side effects of meglumine antimoniate

##plugins.themes.academic_pro.article.details##

References

  1. Dedet JP. Les leishmanioses. Paris: Ellipses/Aupelfuref, 1999:213.
  2. Chulay JD, Fleckenstein L, Smith DH. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibiogluconate or meglumine antimoniate. Trans R SocTrop Med Hyg 1988; 82:69-72.
  3. Dramitika SA, Falcao CAB, De Oliveira FB et al. Role of residual SbIII in meglumine antimoniate cytotoxicity and MRP 1 mediated resistance. Chemico-Biological interactions 2006; 160: 217-24.
  4. Hantson P, Luyasu S, Haufroid V, Lambert M. antimony excretion in a patient with renal impairment during maglumine antimony therapy. Pharmacotherapy 2000; 20: 1141-3.
  5. Buffet P, Caumes E, Gentilini M. traitement des leishmanioses cutanées localisées. Ann Dermatol Venereol 1994 ; 121 :503-511.
  6. Masmoudi A, Maalej N, Mseddi M et al. Glucantime® par voie parentérale, bénéfice versus toxicité. Médecine et maladies infectieuses 2005 ; 35 : 42-5.
  7. Azeredo RB, Mendoça SCF. An intermittent schedule is better than continous regiman of antimonial therapy for cutaneous leishmaniasis in the municipality of Rio de Janeiro. Rev Soc Bras Med Trpo 2002; 35:477-81.
  8. Sierra Romero GA, Flores EMM, Noronha EF. High frequency of skin reaction in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals. Mem Inst Oswaldo Cruz Rio de Janeiro 2003; 98:145-9.
  9. Anderson EM, Cruz SM, Lianos CA et al. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 2005; 72: 133-7.
  10. Saldanha ACR, Sierra GA, Merchan HE et al. Estoudo comparative entre estibiogluconato de sodio e antimoniato de meglumina no tratamento da leishmaniose. Rev Soc Bras Trop 1999 ; 32 :383-7.
  11. Katlama C, Regenier B, Ben Salah N et al. Toxicité du Glucantime®. Ann Med Interne 1985 ; 136 : 321-2.
  12. Mc Bride MO, Linney M, Davidson RN et al. Pancreatitis necrosis following treatment of leishmaniasis with sodium stibiogluconate. Clin inf Dis 1995; 21:710.
  13. Ortega J, Alcazar MD, De La Torre MD et al. Pentavalent antimonial induced torsade de pointe. J Electrocardiol 1997 ; 30 : 143-5.
  14. Veiga JPR, Wollf ER, Sampaio JH et al. Renal tubular dysphonction in patient with mucocutaneous leishmaniasis treated with pentavalent antimonial. Lancet 1983; 569.
  15. Soto J, Buffet P, Grol M et al.successful treatment of colombian cutaneous leishmaniasis with 4 injections of pentamidine. Am J Trop Med Hyg 1994; 50:107-11.
  16. Asilian A, Sadeghinia A, Faghihi G et al. a comparative study of the efficacity of combined cryotherapy and intralesional meglumine antimoniate vs cryotherapy and meglumine antimoniate alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43:281-3.
  17. Pradinaud R. Leishmaniose cutanée.In: Dubertret L, et al. , editors. Thérapeutique dermatologique. Paris : Flammarion ed 2001.:.433-8